Efficacy of follitropin alfa versus follitropin beta in Indian women - impact on oocyte yield and pregnancy outcome: a retrospective study
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20261840Keywords:
Follitropin alfa and beta, Indian, ICSI, Oocyte, PregnancyAbstract
Background: Recombinant follicle-stimulating hormone preparations, Follitropin alfa and Follitropin beta, are widely used for controlled ovarian stimulation in IVF/ICSI. Evidence comparing their reproductive outcomes in Indian women remains limited. This study aims to compare the efficacy of follitropin alfa and follitropin beta on oocyte yield and pregnancy outcomes among Indian women.
Methods: Women younger than 40 years who underwent their first ovarian stimulation cycle with either follitropin alfa or follitropin beta were included after applying the exclusion criteria. Their demographic data, follicular growth, gonadotropin dose used and duration of stimulation, oocyte yield, embryological and pregnancy outcome data are retrieved and compared.
Results: In this cohort of 177 patients 115 women underwent stimulation using follitropin alfa and 62 women with follitropin beta. Baseline demographic, clinical characteristics and ovarian indices were comparable. Follitropin alfa significantly produced higher oocyte (16.33±8.90 vs. 13.13±7.01) and top- intermediate quality embryo yield (8.92±5.46 vs. 7.19±4.04) than follitropin beta in a dose-independent manner, while clinical pregnancy rates (47.0% vs. 61.3%) and cumulative live birth rates (38.3% vs. 48.4%) were comparable between the groups in Indian women who underwent controlled ovarian stimulation.
Conclusions: The study provides encouraging evidence that in both the overall cohort and age-stratified analyses, follitropin alfa had a clear advantage in oocyte and embryo yield but no definitive superiority in final reproductive outcomes when compared to follitropin beta.
References
Dias JA, Ulloa-Aguirre A. New human follitropin preparations: how glycan structural differences may affect biochemical and biological function and clinical effect. Front Endocrinol (Lausanne). 2021;12:636038.
Lee IT, Berger DS, Koelper N, Senapati S, Mainigi M. Race, ovarian responsiveness, and live birth after in vitro fertilization. Fertil Steril. 2023;120(5):1023-32.
Patel AP, Patel JA, Cruz M, Gupte-Shah A, Garcia Velasco JA, Banker MR. Ethnicity is an independent predictor of IVF ICSI outcome: a study of 5,549 cycles in Spain and India. Gynecol Endocrinol. 2016;32(10):819-22.
Coticchio G, Ahlström A, Arroyo G, Balaban B, Campbell A, De Los Santos MJ, et al. The Istanbul consensus update: a revised ESHRE/ALPHA consensus on oocyte and embryo static and dynamic morphological assessment. Hum Reprod. 2025;40(6):989-1035.
Galway AB, Hsueh AJ, Keene JL, Yamoto M, Fauser BC, Boime I. In vitro and in vivo bioactivity of recombinant human follicle-stimulating hormone and partially deglycosylated variants secreted by transfected eukaryotic cell lines. Endocrinology. 1990;127(1):93-100.
Williams RS, Vensel T, Sistrom CL, Kipersztok S, Rhoton-Vlasak A, Drury K. Pregnancy rates in varying age groups after in vitro fertilization: a comparison of follitropin alfa (Gonal-F) and follitropin beta (Follistim). Am J Obstet Gynecol. 2003;189(2):342-6.
Cao JX, Song JY. Follitropin alpha versus follitropin beta in IVF/ICSI cycle: a retrospective cohort study. Drug des devel ther. 2024;18:4359-69.
Bordewijk EM, Mol F, Van der Veen F, Van Wely M. Required amount of rFSH, HP-hMG and HP-FSH to reach a live birth: a systematic review and meta-analysis. Hum Reprod Open. 2019;2019(3):hoz008.
Orvieto R, Nahum R, Rabinson J, Ashkenazi J, Anteby EY, Meltcer S. Follitropin-alpha (Gonal-F) versus follitropin-beta (Puregon) in controlled ovarian hyperstimulation for in vitro fertilization: is there any difference?. Fertil Steril. 2009;91(4):1522-5.
Van den Haute L, Drakopoulos P, Verheyen G, De Vos M, Tournaye H, Blockeel C. Follitropin alpha versus beta in a first GnRH antagonist ICSI cycle: a retrospective cohort study. Reprod Biomed Online. 2021;43(4):655-62.
Coomarasamy A, Afnan M, Cheema D, Van der Veen F, Bossuyt PM, Van Wely M, et al. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod. 2008;23(2):310-5.
Al-Inany HG, Abou-Setta AM, Aboulghar MA. Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis. Reprod Biomed Online. 2008;16(1):81-8.
Wang P, Zhao C, Xu W, Sun H, Zhang Q, Li Y, et al. The association between the number of oocytes retrieved and cumulative live birth rate in different female age strata. Sci Rep. 2023;13:14516.
Setti AS, Braga DP, Iaconelli A, Borges E. Ovarian stimulation with luteinizing hormone supplementation: the impact of timing on ovarian response and ICSI outcomes. JBRA Assist Reprod. 2023;27(2):215-22.
Downloads
Published
How to Cite
Issue
Section
